PBRM1-BD2-IN-2

Cat. No.:	HY-151529
CAS No.:	2819989-57-4
Molecular Formula:	$C_{14}H_9Cl_2FN_2O$
Molecular Weight:	311.14
Target:	Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PBRM1-BD2-IN-2 is a selective and cell-active polybromo-1 (PBRM1) bromodomain inhibitor. PBRM1-BD2-IN-2 has binding affinity and inhibitory activity for PBRM1-BD2 with K_d and IC_{50} values of 9.3 μM and 1.0 μM, respectively. PBRM1-BD2-IN-2 can be used for the research of cancer[1].
IC_{50} & Target	Kd: 9.3 μM (PBRM1-BD2), 10.1 μM (PBRM1-BD5), 18.4 μM (SMARCA2B), 69 μM (SMARCA4)[1]. IC50: 1.0 μM (PBRM1-BD2)[1].
In Vitro	PBRM1-BD2-IN-2 (0, 0.1, 1, and 10 μM; 5 days) selectively inhibit growth of a PBRM1-dependent prostate cancer cell line[1]. PBRM1-BD2-IN-2 has binding affinity for PBRM1-BD2, PBRM1-BD5, SMARCA2B amd SMARCA4 with K_d values of 9.3 μM, 10.1 μM, 18.4 μM and 69 μM, respectively[1]. PBRM1-BD2-IN-2 has inhibitory activity for PBRM1-BD2 with IC_{50} value of 1.0 μM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay[1]

Cell Line:	Human prostate cell lines LNCaP, PC3, and RWPE-1
Concentration:	0, 0.1, 1, and 10 μM
Incubation Time:	5 days
Result:	Inhibited LNCaP growth at higher concentrations.

REFERENCES

[1]. Shifali Shishodia, et al. Selective and Cell-Active PBRM1 Bromodomain Inhibitors Discovered through NMR Fragment Screening. J Med Chem. 2022 Oct 13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA